JAK1/JAK2 inhibitor baricitinib ameliorates sepsis-induced acute kidney injury in rats
Küçük Resim Yok
Tarih
2025
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: Baricitinib (Bar), used in the management of rheumatoid arthritis, is a selective inhibitor of JAK1/ JAK2. Studies have shown that it inhibits the intracellular signaling of many proinflammatory cytokines by suppressing STAT3 activation. Increased expression and activity of JAK1/JAK2 and STAT3 are associated with kidney damage. Here, we examined the effects of the JAK1/JAK2 inhibitor baricitinib (Bar) on kidney damage in a sepsis model created with cecal ligation and puncture (CLP) in rats. Methods: Rats were divided into four groups: control, CLP, CLP + Bar 3 mg kg- 1, and CLP + Bar 10 mg kg- 1. The cecum of animals to which CLP was applied was first ligated distally, then punctured with a needle to allow the fecal content to spread into the abdominal cavity. Two different doses of Bar (3 mg kg- 1, 10 mg kg- 1) were applied to the treatment groups. Biochemical examinations were performed on the sera of animals sacrificed 24 h after CLP, while histopathological and immunohistochemical examinations were performed on kidney tissue. Results
Açıklama
Anahtar Kelimeler
Sepsis, Cecal ligation and puncture, Baricitinib, JAK1/JAK2
Kaynak
European Journal of Pharmacology
WoS Q Değeri
Q1
Scopus Q Değeri
Q1
Cilt
1002
